

Supplementary Table 1 Serological analysis of experimental animals after stent placement (mean \pm SD)

	Group	Day 0	Day 1	Day 3	Day 7	Day 14	Day 28
WBC ($\times 10^9/L$)	Control	18.6 \pm 2.5	19.1 \pm 2.9	19.6 \pm 3.4	20.5 \pm 3.1	19.9 \pm 2.4	18.7 \pm 2.6
	PLCL-0	19.8 \pm 2.7	20.6 \pm 3.3	20.9 \pm 3.1	21.5 \pm 3.4	20.8 \pm 2.9	19.7 \pm 3.2
	PLCL-G	19.2 \pm 1.9	21.2 \pm 3.3	22.9 \pm 3.5	22.2 \pm 3.7	21.9 \pm 3.6	20.2 \pm 3.6
	PLCL-C	20.1 \pm 2.5	21.7 \pm 2.8	23.2 \pm 3.7	22.7 \pm 3.8	22.3 \pm 4.1	21.4 \pm 3.9
	PLCL-G&C	20.3 \pm 2.9	21.8 \pm 3.7	23.4 \pm 3.8	23.1 \pm 4.2	22.6 \pm 2.5	21.7 \pm 3.6
ALT (U/L)	Control	39 \pm 6.1	186 \pm 12.6	203 \pm 18.1	99 \pm 13.1	63 \pm 11.7	48 \pm 7.4
	PLCL-0	43 \pm 4.4	178 \pm 18.1	237 \pm 23.7	113 \pm 17.7	62 \pm 9.6	51 \pm 5.7
	PLCL-G	41 \pm 5.1	194 \pm 21.3	226 \pm 26.2	137 \pm 22.5	69 \pm 11.4	55 \pm 7.9
	PLCL-C	40 \pm 5.3	183 \pm 23.8	218 \pm 24.6	119 \pm 20.4	61 \pm 9.2	47 \pm 8.2
	PLCL-G&C	37 \pm 5.7	203 \pm 22.4	234 \pm 27.7	128 \pm 18.6	73 \pm 11.9	56 \pm 9.3
AST (U/L)	Control	41 \pm 5.2	201 \pm 31.4	243 \pm 36.2	109 \pm 21.1	59 \pm 13.2	49 \pm 5.7
	PLCL-0	44 \pm 5.4	223 \pm 39.2	257 \pm 39.7	99 \pm 18.8	58 \pm 13.7	53 \pm 3.6
	PLCL-G	40 \pm 6.1	217 \pm 31.8	233 \pm 31.3	117 \pm 20.3	67 \pm 15.1	60 \pm 7.9
	PLCL-C	44 \pm 7.2	209 \pm 34.6	246 \pm 42.6	105 \pm 28.8	59 \pm 12.4	55 \pm 6.2
	PLCL-G&C	46 \pm 5.7	227 \pm 43.8	261 \pm 48.2	113 \pm 33.7	69 \pm 15.9	63 \pm 7.1
γ-GT (U/L)	Control	43 \pm 5.1	271 \pm 52.3	168 \pm 36.6	115 \pm 28.2	65 \pm 23.1	59 \pm 17.5
	PLCL-0	46 \pm 6.5	305 \pm 63.4	216 \pm 47.2	103 \pm 31.5	63 \pm 19.7	58 \pm 12.5
	PLCL-G	41 \pm 5.9	317 \pm 69.5	205 \pm 49.3	114 \pm 36.7	72 \pm 17.2	63 \pm 16.1
	PLCL-C	47 \pm 5.3	322 \pm 73.1	211 \pm 45.8	107 \pm 33.4	69 \pm 22.5	65 \pm 18.7
	PLCL-G&C	44 \pm 4.8	343 \pm 76.5	207 \pm 38.5	111 \pm 38.4	70 \pm 27.8	61 \pm 19.7
TBil (μmol/L)	Control	6.2 \pm 2.7	20.1 \pm 3.7	17.5 \pm 4.8	15.9 \pm 3.4	7.3 \pm 2.6	6.5 \pm 2.8
	PLCL-0	5.5 \pm 1.8	22.8 \pm 4.6	19.3 \pm 5.7	16.5 \pm 4.5	8.2 \pm 2.1	6.8 \pm 1.6
	PLCL-G	6.5 \pm 3.5	23.9 \pm 5.7	20.2 \pm 4.1	17.1 \pm 5.8	7.7 \pm 3.2	6.2 \pm 2.0
	PLCL-C	6.3 \pm 3.7	22.3 \pm 4.4	17.4 \pm 5.3	15.7 \pm 5.3	7.8 \pm 3.5	6.3 \pm 2.5
	PLCL-G&C	6.1 \pm 2.3	22.8 \pm 6.1	18.8 \pm 6.5	14.7 \pm 5.4	7.9 \pm 2.8	6.7 \pm 2.1
amylase (U/L)	Control	2138 \pm 248	2316 \pm 267	2213 \pm 285	2185 \pm 254	2283 \pm 297	2166 \pm 281
	PLCL-0	2235 \pm 335	2487 \pm 314	2198 \pm 324	2177 \pm 263	2203 \pm 307	2217 \pm 293
	PLCL-G	2157 \pm 274	2396 \pm 281	2163 \pm 288	2213 \pm 274	2194 \pm 279	2198 \pm 271
	PLCL-C	2218 \pm 291	2423 \pm 339	2287 \pm 303	2223 \pm 301	2394 \pm 322	2213 \pm 303
	PLCL-G&C	2196 \pm 252	2490 \pm 357	2207 \pm 317	2157 \pm 287	2275 \pm 295	2187 \pm 314
Creatinine (μmol/L)	Control	106 \pm 17.2	117 \pm 21.6	123 \pm 25.2	112 \pm 26.7	108 \pm 29.1	114 \pm 33.2
	PLCL-0	114 \pm 21.8	125 \pm 24.9	128 \pm 27.3	119 \pm 21.5	111 \pm 26.2	108 \pm 25.7
	PLCL-G	109 \pm 18.3	118 \pm 19.1	123 \pm 23.6	107 \pm 32.2	106 \pm 31.3	112 \pm 26.5
	PLCL-C	104 \pm 15.5	115 \pm 17.3	118 \pm 31.3	110 \pm 21.9	115 \pm 23.2	109 \pm 31.1
	PLCL-G&C	107 \pm 20.6	109 \pm 22.3	121 \pm 26.4	108 \pm 28.7	113 \pm 28.1	116 \pm 24.4

ALT: alanine aminotransferase; AST: aspartate aminotransferase; PLCL-0: stent coated with a non-drug loaded PLCL nanofilm; PLCL-CIS: stent coated with a CIS-eluting PLCL nanofilm; PLCL-GEM: stent coated with a GEM-eluting PLCL nanofilm; PLCL-G&C: stent coated with a PLCL nanofilm eluting both GEM and CIS; TBil: total bilirubin; WBC, white blood cell; γ -GT, γ -glutamyl transpeptidase.